Tau protein (encoded by the MAPT gene) is an attractive therapeutic target for the treatment of Alzheimer’s disease (AD) and other “tauopathies”, where aggregated tau pathology accumulates in neurons. Since tau dep...Tau protein (encoded by the MAPT gene) is an attractive therapeutic target for the treatment of Alzheimer’s disease (AD) and other “tauopathies”, where aggregated tau pathology accumulates in neurons. Since tau deposition is strongly associated with cognitive dysfunction in AD, and tau purportedly mediates the toxicity of β-amyloid, therapies developed to reduce tau or its phosphorylation have been tested preclinically and in several small-scale clinical trials[1]. However, caveats for tau-targeting therapy include the limited understanding of its physiological functions and the complicated interactions between its post-translational modifications, aggregation, and cellular toxicity.展开更多
基金supported by the National Clinical Research Center for Geriatrics of West China Hospital (Z2021LC001)the West China Hospital 1.3.5 Project for Disciplines of Excellence(ZYYC20009)。
文摘Tau protein (encoded by the MAPT gene) is an attractive therapeutic target for the treatment of Alzheimer’s disease (AD) and other “tauopathies”, where aggregated tau pathology accumulates in neurons. Since tau deposition is strongly associated with cognitive dysfunction in AD, and tau purportedly mediates the toxicity of β-amyloid, therapies developed to reduce tau or its phosphorylation have been tested preclinically and in several small-scale clinical trials[1]. However, caveats for tau-targeting therapy include the limited understanding of its physiological functions and the complicated interactions between its post-translational modifications, aggregation, and cellular toxicity.
